Indivior PLC (NASDAQ:INDV) Short Interest Update

Indivior PLC (NASDAQ:INDV) was the target of a large increase in short interest in July. As of July 15th, there was short interest totalling 601,700 shares, an increase of 532.0% from the June 30th total of 95,200 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 320,700 shares, the days-to-cover ratio is currently 1.9 days.

Wall Street Analyst Weigh In

INDV has been the subject of a number of research analyst reports. Piper Sandler initiated coverage on shares of Indivior in a report on Tuesday. They set an “overweight” rating and a $22.00 price objective for the company. Craig Hallum cut their target price on shares of Indivior from $37.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday, July 10th.

Institutional Trading of Indivior

A number of institutional investors have recently bought and sold shares of INDV. Bank of New York Mellon Corp bought a new stake in shares of Indivior during the second quarter worth $188,000. FourWorld Capital Management LLC bought a new stake in shares of Indivior during the first quarter worth $2,215,000. Janus Henderson Group PLC lifted its position in shares of Indivior by 14.2% during the first quarter. Janus Henderson Group PLC now owns 440,121 shares of the company’s stock worth $9,424,000 after purchasing an additional 54,750 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of Indivior during the first quarter worth $1,523,000. Finally, Toronto Dominion Bank lifted its position in shares of Indivior by 58.0% during the first quarter. Toronto Dominion Bank now owns 2,094,865 shares of the company’s stock worth $44,872,000 after purchasing an additional 769,000 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors.

Indivior Price Performance

Shares of INDV stock traded down $0.30 on Friday, reaching $12.79. The company’s stock had a trading volume of 1,487,673 shares, compared to its average volume of 920,827. The stock’s fifty day simple moving average is $15.09 and its 200-day simple moving average is $17.64. Indivior has a 1 year low of $9.14 and a 1 year high of $24.11. The company has a current ratio of 0.92, a quick ratio of 0.74 and a debt-to-equity ratio of 23.50. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of 1,279.00 and a beta of 0.69.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Thursday, April 25th. The company reported $0.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.01). The company had revenue of $284.00 million during the quarter, compared to the consensus estimate of $300.00 million. Indivior had a negative return on equity of 4,735.71% and a negative net margin of 12.29%. Analysts forecast that Indivior will post 1.76 earnings per share for the current fiscal year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.